TY - JOUR AU - Hurwitz, H. AU - Fehrenbacher, L. AU - Novotny, W. AU - Cartwright, T. AU - Hainsworth, J. AU - Heim, W. PY - 2004 DA - 2004// TI - Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa032691 DO - 10.1056/NEJMoa032691 ID - Hurwitz2004 ER - TY - JOUR AU - Sandler, A. AU - Gray, R. AU - Perry, M. C. AU - Brahmer, J. AU - Schiller, J. H. AU - Dowlati, A. PY - 2006 DA - 2006// TI - Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa061884 DO - 10.1056/NEJMoa061884 ID - Sandler2006 ER - TY - JOUR AU - Carrato, A. AU - Swieboda-Sadlej, A. AU - Staszewska-Skurczynska, M. AU - Lim, R. AU - Roman, L. AU - Shparyk, Y. PY - 2013 DA - 2013// TI - Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.45.1930 DO - 10.1200/JCO.2012.45.1930 ID - Carrato2013 ER - TY - JOUR AU - Bergh, J. AU - Bondarenko, I. M. AU - Lichinitser, M. R. AU - Liljegren, A. AU - Greil, R. AU - Voytko, N. L. PY - 2012 DA - 2012// TI - First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.35.7376 DO - 10.1200/JCO.2011.35.7376 ID - Bergh2012 ER - TY - JOUR AU - Paz-Ares, L. G. AU - Biesma, B. AU - Heigener, D. AU - Pawel, J. AU - Eisen, T. AU - Bennouna, J. PY - 2012 DA - 2012// TI - Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.7646 DO - 10.1200/JCO.2011.39.7646 ID - Paz-Ares2012 ER - TY - JOUR AU - Duda, D. G. AU - Batchelor, T. T. AU - Willett, C. G. AU - Jain, R. K. PY - 2007 DA - 2007// TI - VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects JO - Trends Mol Med VL - 13 UR - https://doi.org/10.1016/j.molmed.2007.04.001 DO - 10.1016/j.molmed.2007.04.001 ID - Duda2007 ER - TY - JOUR AU - Willett, C. G. AU - Boucher, Y. AU - Tomaso, R. AU - Duda, D. G. AU - Munn, L. L. AU - Tong, R. T. PY - 2004 DA - 2004// TI - Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer JO - Nat Med VL - 10 UR - https://doi.org/10.1038/nm988 DO - 10.1038/nm988 ID - Willett2004 ER - TY - JOUR AU - Gradishar, W. J. AU - Kaklamani, V. AU - Sahoo, T. P. AU - Lokanatha, D. AU - Raina, V. AU - Bondarde, S. PY - 2013 DA - 2013// TI - A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.08.005 DO - 10.1016/j.ejca.2012.08.005 ID - Gradishar2013 ER - TY - JOUR AU - Baselga, J. AU - Roche, H. AU - Costa, F. AU - Getulio Martins Segalla, J. AU - Pinczowski, H. AU - Ma Ciruelos, E. PY - 2009 DA - 2009// TI - SOLTI-0701: A multinational double-blind, randomized Phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC) JO - Cancer Res VL - 69 ID - Baselga2009 ER - TY - JOUR AU - Winkler, F. AU - Kozin, S. V. AU - Tong, R. T. AU - Chae, S. S. AU - Booth, M. F. AU - Garkavtsev, I. PY - 2004 DA - 2004// TI - Kinetics of vascular normalization by VEGFR2 blockage governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteases JO - Cancer Cell VL - 6 ID - Winkler2004 ER - TY - JOUR AU - Jain, R. K. PY - 2005 DA - 2005// TI - Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy JO - Science VL - 307 UR - https://doi.org/10.1126/science.1104819 DO - 10.1126/science.1104819 ID - Jain2005 ER - TY - JOUR AU - Wong, A. L. A. AU - Sundar, R. AU - Wang, T. -. T. AU - Ng, T. -. C. AU - Zhang, B. AU - Tan, S. -. H. PY - 2016 DA - 2016// TI - Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.11596 DO - 10.18632/oncotarget.11596 ID - Wong2016 ER - TY - JOUR AU - Schulz, K. F. AU - Altman, D. G. AU - Moher, D. PY - 2010 DA - 2010// TI - CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials JO - BMC Med VL - 8 UR - https://doi.org/10.1186/1741-7015-8-18 DO - 10.1186/1741-7015-8-18 ID - Schulz2010 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Goh, B. C. AU - Lee, S. C. AU - Wang, L. Z. AU - Fan, L. AU - Guo, J. Y. AU - Lamba, J. PY - 2002 DA - 2002// TI - Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.01.025 DO - 10.1200/JCO.2002.01.025 ID - Goh2002 ER - TY - JOUR AU - Nabholtz, J. M. AU - Senn, H. J. AU - Bezwoda, W. R. AU - Melnychuk, D. AU - Deschenes, L. AU - Douma, J. PY - 1999 DA - 1999// TI - Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 study group JO - J Clin Oncol VL - 17 UR - https://doi.org/10.1200/JCO.1999.17.5.1413 DO - 10.1200/JCO.1999.17.5.1413 ID - Nabholtz1999 ER - TY - JOUR AU - Fossella, F. V. AU - DeVore, R. AU - Kerr, R. N. AU - Crawford, J. AU - Natale, R. R. AU - Dunphy, F. PY - 2000 DA - 2000// TI - Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung Cancer study group JO - J Clin Oncol VL - 18 UR - https://doi.org/10.1200/JCO.2000.18.12.2354 DO - 10.1200/JCO.2000.18.12.2354 ID - Fossella2000 ER - TY - JOUR AU - Heist, R. S. AU - Wang, X. AU - Hodgson, L. AU - Otterson, G. A. AU - Stinchcombe, T. E. AU - Gandhi, L. PY - 2014 DA - 2014// TI - CALGB 30704 (Alliance): a randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non small-cell lung cancer JO - J Thorac Oncol VL - 9 UR - https://doi.org/10.1097/JTO.0000000000000071 DO - 10.1097/JTO.0000000000000071 ID - Heist2014 ER - TY - JOUR AU - Reck, M. AU - Kaiser, R. AU - Mellemgaard, A. AU - Douillard, J. -. Y. AU - Orlov, S. AU - Krzakowski, M. PY - 2014 DA - 2014// TI - Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-lung 1): a phase 3, double-blind, randomised controlled trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70586-2 DO - 10.1016/S1470-2045(13)70586-2 ID - Reck2014 ER - TY - JOUR AU - Garon, E. B. AU - Ciuleani, T. -. E. AU - Arrieta, O. AU - Prabhash, K. AU - Syrigos, K. N. AU - Goksel, T. PY - 2014 DA - 2014// TI - Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum based therapy (REVEL): a multicenter, double-blind, randomised phase 3 trial JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(14)60845-X DO - 10.1016/S0140-6736(14)60845-X ID - Garon2014 ER - TY - JOUR AU - Miller, K. AU - Wang, M. AU - Gralow, J. AU - Dickler, M. AU - Cobleigh, M. AU - Perez, E. A. PY - 2007 DA - 2007// TI - Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMoa072113 DO - 10.1056/NEJMoa072113 ID - Miller2007 ER - TY - STD TI - Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252–60. ID - ref22 ER -